Anson Funds Management LP acquired a new stake in CEL-SCI Co. (NYSEAMERICAN:CVM) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 263,158 shares of the company’s stock, valued at approximately $423,000. CEL-SCI accounts for about 0.3% of Anson Funds Management LP’s holdings, making the stock its 27th biggest position.
Shares of CEL-SCI Co. (NYSEAMERICAN CVM) opened at $1.79 on Wednesday. The firm has a market capitalization of $25.49, a price-to-earnings ratio of -0.66 and a beta of -1.29. CEL-SCI Co. has a twelve month low of $1.46 and a twelve month high of $4.00.
CEL-SCI (NYSEAMERICAN:CVM) last announced its quarterly earnings data on Monday, February 12th. The company reported ($0.53) earnings per share for the quarter. The firm had revenue of $0.11 million during the quarter.
CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines.
Want to see what other hedge funds are holding CVM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CEL-SCI Co. (NYSEAMERICAN:CVM).
Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.